Transcranial Magnetic Stimulation as a Translational Biomarker in Early-Phase Anti-Seizure Medication Development: A Randomized, Double-Blind, Placebo-Controlled Study in Generalized Epilepsy.
Catherine M E de Cuba, Titia Q Ruijs, Annika A de Goede et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized, double-blind, placebo-controlled study evaluated transcranial magnetic stimulation (TMS) as a biomarker for anti-seizure medication effects in patients with generalized epilepsy. The study found that levetiracetam significantly reduced motor-evoked potential amplitude and enhanced long-interval intracortical inhibition, with larger effects observed in levetiracetam-naïve patients, indicating TMS-derived endpoints may serve as valuable biomarkers in early-phase drug development.
Key findings
- Levetiracetam significantly reduced motor-evoked potential amplitude and enhanced long-interval intracortical inhibition.
- Larger effect sizes were observed in levetiracetam-naïve patients compared to those already on the medication.
- TMS-EEG revealed distinct modulation patterns in TMS-evoked potential components between patient groups.
Why it matters
The study highlights the potential of TMS-derived biomarkers to assess the pharmacodynamic effects of anti-seizure medications, which could facilitate the development of new treatments for epilepsy, particularly in treatment-resistant cases.